Oncology

Ivonescimab plus chemotherapy improved survival compared with current standard treatment durvalumab plus chemotherapy in advanced biliary tract cancer.

Adding darolutamide to hormone therapy and radiotherapy improved metastasis-free survival in high-risk prostate cancer, according to research presented at ESMO 2026.

Osimertinib plus savolitinib cut death risk by 32% versus chemotherapy in selected patients with resistant lung cancer, according to new trial results presented at ESMO 2026.

Intismeran improved melanoma outcomes and reduced reoccurrence by over 40%, but leaked trial data fell short of investor expectations, hitting Moderna and Merck shares.